Direct-to-consumer genetic testing kits vary in predictions of disease risk

July 17, 2013

(Medical Xpress)—An in-depth analysis and comparison study conducted by investigators at Emory's Rollins School of Public Health demonstrated variations in predicted disease risks by companies that offer direct-to-consumer personal genome testing.

Led by Cecile Janssens, PhD, research professor of Epidemiology, the team investigated DNA test results from three "direct- to-consumer" genome testing companies (23andMe, deCODEme, and Navigenics) to assess and compare their predictive abilities. Results show that predicted risks differed among the companies and were contradictory for certain traits in certain individuals.

The complete findings are available in the online edition of Genetics in Medicine.

"Although two of the companies that we studied are no longer operating, and sequencing is becoming less expensive and testing such as this is increasingly popular," explains Janssens. "The methods used for predicting these types of results are of important concern."

Test results provided by the three companies indicated an individual's risks for a large number of diseases. The study was conducted by creating DNA data for a hypothetical population of 100,000 individuals which is a less expensive and equally valid method for demonstrating the variations in predicted risk among the companies.

Predicted risks were calculated using the prediction methods of the three companies, obtained from their websites. Predicted risks were assessed and compared for six diseases: , prostate cancer, , Crohn disease, age-related , and .

The variations in predicted risks were explained by three factors:

  • The companies considered a different number of genetic variants in the risk calculations. Generally a larger difference in the number of variants implied more variation in predicted risks.
  • All three companies used an estimate for the average population disease risk as a starting point for their predictions. Differences in average risks affect predicted risks of all consumers to the same extent. For example, when the average odds is two times higher, all predicted odds are also two times higher.
  • The companies applied different mathematical formulas. The formulas of two companies led to an overestimation of risks when predicted risks were higher and even predicted risks that were higher than 100 percent.

"Our study provides insight into the methodology and performance of risk estimation for personal genome tests," Janssens explains. "Future efforts to design predictive models will benefit from understanding the strengths and limitations of these current models and formulas."

Explore further: DTC genetic tests neither accurate in their predictions nor beneficial to individuals

More information: … full/gim201380a.html

Related Stories

DTC genetic tests neither accurate in their predictions nor beneficial to individuals

May 30, 2011
Amsterdam, The Netherlands: Direct-to-consumer (DTC) genetic tests give inaccurate predictions of disease risks and many European geneticists believe that some of them should be banned, the annual conference of the European ...

Genetic testing kits get closer look in Loyola study

July 15, 2013
(Medical Xpress)—Several companies sell genetic testing directly to consumers, but little research has been done on how consumers experience such tests. The tests have raised questions about the validity and accuracy of ...

Meta-analysis confirms common painkillers increase risk of heart problems and death but suggests size of these risks can

May 29, 2013
NSAIDs have been the cornerstone in managing pain in people with inflammatory disorders like rheumatoid arthritis, and are some of the most commonly used drugs worldwide. Earlier research has linked their use with an increased ...

Comparing family history and genetic tests for predicting complex disease risk

October 15, 2012
In a new theoretical study, 23andMe, the personal genetics company, developed a mathematical model which shows that family history and genetic tests offer different strengths. The study results suggest that both family history ...

Patients see benefits and risks to direct-to-consumer genetics tests

May 10, 2012
Patients see potential benefits from direct-to-consumer genetic testing, but are also concerned about how test results will be used, and generally are unwilling to pay more than $10 or $20 for them, according to focus groups ...

Recommended for you

Scientists provide insight into genetic basis of neuropsychiatric disorders

July 21, 2017
A study by scientists at the Children's Medical Center Research Institute at UT Southwestern (CRI) is providing insight into the genetic basis of neuropsychiatric disorders. In this research, the first mouse model of a mutation ...

Scientists identify new way cells turn off genes

July 19, 2017
Cells have more than one trick up their sleeve for controlling certain genes that regulate fetal growth and development.

South Asian genomes could be boon for disease research, scientists say

July 18, 2017
The Indian subcontinent's massive population is nearing 1.5 billion according to recent accounts. But that population is far from monolithic; it's made up of nearly 5,000 well-defined sub-groups, making the region one of ...

Mutant yeast reveals details of the aberrant genomic machinery of children's high-grade gliomas

July 18, 2017
St. Jude Children's Research Hospital biologists have used engineered yeast cells to discover how a mutation that is frequently found in pediatric brain tumor high-grade glioma triggers a cascade of genomic malfunctions.

Late-breaking mutations may play an important role in autism

July 17, 2017
A study of nearly 6,000 families, combining three genetic sequencing technologies, finds that mutations that occur after conception play an important role in autism. A team led by investigators at Boston Children's Hospital ...

Newly discovered gene variants link innate immunity and Alzheimer's disease

July 17, 2017
Three new gene variants, found in a genome wide association study of Alzheimer's disease (AD), point to the brain's immune cells in the onset of the disorder. These genes encode three proteins that are found in microglia, ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.